About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tgfbr1tm1.1Karl
targeted mutation 1.1, Stefan Karlsson
MGI:2680164
Summary 10 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(Tie1-cre)9Ref/0
either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ) MGI:3623408
cn2
Tgfbr1tm1Karl/Tgfbr1tm1.1Karl
Tg(GATA5-cre)1Krc/0
involves: 129 MGI:4836601
cn3
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(Tie1-cre)9Ref/?
Gt(ROSA)26Sortm1Sor/?
involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6J MGI:3767613
cn4
Ptentm1Hwu/Ptentm1Hwu
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(KRT14-cre/ERT)20Efu/0
involves: 129 * 129S4/SvJae * C57BL/6 * CD-1 * FVB/N MGI:5487550
cn5
Tg(Col2a1-cre/ERT2)1Dic/0
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
involves: 129 * C57BL/6 MGI:6306137
cn6
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(Mx1-cre)1Cgn/0
involves: 129 * C57BL/6 * CBA MGI:2680169
cn7
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(Acvrl1-cre)L1Spo/0
involves: 129 * FVB MGI:4398919
cn8
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(Nes-cre)1Atp/0
involves: 129 * FVB/N MGI:6441946
cn9
Cd207tm2.1(cre)Bjec/Cd207+
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
involves: 129S4/SvJaeSor * C57BL/6 MGI:5308087
cn10
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+
involves: 129S/Sv * C57BL/6 * FVB/N MGI:5523277


Genotype
MGI:3623408
cn1
Allelic
Composition
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(Tie1-cre)9Ref/0
Genetic
Background
either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tgfbr1tm1.1Karl mutation (1 available); any Tgfbr1 mutation (36 available)
Tg(Tie1-cre)9Ref mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• embryonic lethality at mid gestation

embryo
• develop similar yolk sac defects as Tgfbr1 null mice

cardiovascular system
• develop similar yolk sac defects as Tgfbr1 null mice




Genotype
MGI:4836601
cn2
Allelic
Composition
Tgfbr1tm1Karl/Tgfbr1tm1.1Karl
Tg(GATA5-cre)1Krc/0
Genetic
Background
involves: 129
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tgfbr1tm1.1Karl mutation (1 available); any Tgfbr1 mutation (36 available)
Tgfbr1tm1Karl mutation (0 available); any Tgfbr1 mutation (36 available)
Tg(GATA5-cre)1Krc mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging

respiratory system
• late lung development is blocked such that lungs appear more cellular and contain immature alveoli and reduced airspace in distal lungs at E18.5 compared to wild-type
• marker analysis indicates that bronchiolar epithelial progenitor cell differentiation is impaired, however alveolar epithelial cell differentiation appears normal
• bronchiolar epithelial progenitor cell differentiation is impaired
• Clara cell numbers are reduced in E18.5 lungs
• lungs are smaller at E15.5
• distal airways are composed of highly disorganized cells
• enlarged airways in the lungs at E15.5

integument
• fail to develop ventral skin




Genotype
MGI:3767613
cn3
Allelic
Composition
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(Tie1-cre)9Ref/?
Gt(ROSA)26Sortm1Sor/?
Genetic
Background
involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1Sor mutation (8 available); any Gt(ROSA)26Sor mutation (956 available)
Tgfbr1tm1.1Karl mutation (1 available); any Tgfbr1 mutation (36 available)
Tg(Tie1-cre)9Ref mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice are present at E9.5 but dead by E12.5

embryo
• mice lack networks of vessels at all stages
• at E9.5, mice appear delayed by 1 day
• yolk sacs possess greater numbers of vascular smooth muscle cells than in wild-type yolk sacs

growth/size/body
• at E9.5, mice appear delayed by 1 day

cardiovascular system
• mice lack networks of vessels at all stages
• at E9.5, hearts exhibit pericardial effusion

homeostasis/metabolism
• at E9.5, hearts exhibit pericardial effusion




Genotype
MGI:5487550
cn4
Allelic
Composition
Ptentm1Hwu/Ptentm1Hwu
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(KRT14-cre/ERT)20Efu/0
Genetic
Background
involves: 129 * 129S4/SvJae * C57BL/6 * CD-1 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptentm1Hwu mutation (16 available); any Pten mutation (82 available)
Tgfbr1tm1.1Karl mutation (1 available); any Tgfbr1 mutation (36 available)
Tg(KRT14-cre/ERT)20Efu mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl Ptentm1Hwu/Ptentm1Hwu Tg(KRT14-cre/ERT)20Efu/0 mice develop anal squamous cell carcinoma

neoplasm
• tamoxifen treated mutants to induce cre-mediated deletion of Tgfbr1 and Pten develop head and neck tumors; papillomas progress to squamous cell carcinoma in the head and neck and oral cavity (J:194652)
• treatment with rapamycin 2 weeks after tamoxifen administration delays initiation and reduces progression of papilloma and onset of squamous cell carcinoma (J:194652)
• rapamycin treatment of mice with already established head and neck squamous cell carcinoma results in regression of those tumors; rapamycin decreases cell proliferation and increases apoptosis in these tumors (J:194652)
• anal neoplasms that develop in tamoxifen treated mice originate from squamous epithelia and not from columnar epithelia, indicating squamous cell carcinoma (J:209026)
• invasion into adjacent muscle tissue is seen in some mice (J:209026)
• anal squamous cell carcinoma shows increased levels of proinflammatory cytokines (J:209026)
• all mice develop head and neck squamous cell carcinomas 16 weeks after tamoxifen induction (J:209026)
• rapamycin treatment 2 weeks after tamoxifen administration decreases cell proliferation, and delays and reduces the progression of anal squamous cell carcinoma (J:209026)
• tamoxifen treated mutants to induce cre-mediated deletion of Tgfbr1 and Pten develop head and neck and oral cavity papillomas that progress to squamous cell carcinoma
• 33% of mice develop visible anal tumors in 6 weeks after tamoxifen treatment

digestive/alimentary system
• 4 weeks after oral tamoxifen treatment for 5 consecutive days, hyperplasia is seen in the perianal areas




Genotype
MGI:6306137
cn5
Allelic
Composition
Tg(Col2a1-cre/ERT2)1Dic/0
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Col2a1-cre/ERT2)1Dic mutation (0 available)
Tgfbr1tm1.1Karl mutation (1 available); any Tgfbr1 mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• tamoxifen-treated mice exhibit progressive degeneration and lesions of the knee articular cartilage from 2-6 months of age
• lesions exhibit as either empty lacuna or confined loss of cartilage tissue
• 3 month old tamoxifen-treated mice show an early osteoarthritis-like phenotype, including loss of proteoglycan content and cartilage tissue and increased number of hypertrophic chondrocytes in articular cartilage
• 6 month old tamoxifen-treated mice exhibit more severe destruction of the articular cartilage, associated with greater loss of proteoglycan content and cartilage, osteophyte formation and increased subchondral bone mass

skeleton
• tamoxifen-treated mice exhibit increased articular chondrocyte apoptosis
• tamoxifen-treated mice exhibit progressive degeneration and lesions of the knee articular cartilage from 2-6 months of age
• lesions exhibit as either empty lacuna or confined loss of cartilage tissue
• 3 month old tamoxifen-treated mice show an early osteoarthritis-like phenotype, including loss of proteoglycan content and cartilage tissue and increased number of hypertrophic chondrocytes in articular cartilage
• 6 month old tamoxifen-treated mice exhibit more severe destruction of the articular cartilage, associated with greater loss of proteoglycan content and cartilage, osteophyte formation and increased subchondral bone mass
• osteophyte formation is seen in 6 month old tamoxifen-treated mice
• tamoxifen-treated mice exhibit synovial hyperplasia
• tamoxifen-treated mice show increased articular cartilage thickness at 2 months of age with zonal disruption and loss of proteoglycan content

cellular
• tamoxifen-treated mice exhibit increased articular chondrocyte apoptosis

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
osteoarthritis DOID:8398 J:271724




Genotype
MGI:2680169
cn6
Allelic
Composition
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(Mx1-cre)1Cgn/0
Genetic
Background
involves: 129 * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tgfbr1tm1.1Karl mutation (1 available); any Tgfbr1 mutation (36 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
N
• normal hematopoiesis and hematopoietic stem cell self renewal and regenerative ability in spite of an increased hematopoietic stem cell proliferative capacity observed in vitro
• hematopoietic stem cells from polyIC-induced mice show increased proliferation recruitment when cultured as single cells under low stimulatory conditions in vitro

cellular
• hematopoietic stem cells from polyIC-induced mice show increased proliferation recruitment when cultured as single cells under low stimulatory conditions in vitro




Genotype
MGI:4398919
cn7
Allelic
Composition
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(Acvrl1-cre)L1Spo/0
Genetic
Background
involves: 129 * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Acvrl1-cre)L1Spo mutation (0 available)
Tgfbr1tm1.1Karl mutation (1 available); any Tgfbr1 mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype
• mice are viable and exhibit normal vasculature

cardiovascular system
N
• mice exhibit normal vasculature




Genotype
MGI:6441946
cn8
Allelic
Composition
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(Nes-cre)1Atp/0
Genetic
Background
involves: 129 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tgfbr1tm1.1Karl mutation (1 available); any Tgfbr1 mutation (36 available)
Tg(Nes-cre)1Atp mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging

craniofacial
• starting at E10, the maxillary process is hypoplastic as a result of dramatic apoptosis occurring at the medial border of the maxillary process bilaterally around E9.5
• TUNEL assays showed increased apoptosis in the mesenchyme of the anterior aspect of the medial nasal process (MNP)
• development of the palatal shelves is delayed at E13.5, suggesting that secondary palate fusion is extremely unlikely (cleft palate not confirmed due to lethality at E15)
• at E13.5, palatal shelves are hypoplastic
• at E13.5, embryos exhibit unilateral, or occasionally, bilateral cleft lip extending into the nostril; overall penetrance of cleft lip is 64%
• TUNEL assays showed decreased apoptosis in the epithelial seam between the medial nasal process (MNP) and the maxillary process (MAX) at E11
• at E11, the contact between the medial (MNP) and lateral nasal processes (LNP) is greatly reduced with no apparent involvement of the MAX, resulting in a very small epithelial seam
• cleft lip may be caused by inadequate contact between the MNP and MAX, due to morphological differences, exacerbated by reduced apoptosis and seam persistence
• occasionally at E13.5
• frequently at E13.5

digestive/alimentary system
• development of the palatal shelves is delayed at E13.5, suggesting that secondary palate fusion is extremely unlikely (cleft palate not confirmed due to lethality at E15)
• at E13.5, palatal shelves are hypoplastic

growth/size/body
• development of the palatal shelves is delayed at E13.5, suggesting that secondary palate fusion is extremely unlikely (cleft palate not confirmed due to lethality at E15)
• at E13.5, palatal shelves are hypoplastic
• at E13.5, embryos exhibit unilateral, or occasionally, bilateral cleft lip extending into the nostril; overall penetrance of cleft lip is 64%
• TUNEL assays showed decreased apoptosis in the epithelial seam between the medial nasal process (MNP) and the maxillary process (MAX) at E11
• at E11, the contact between the medial (MNP) and lateral nasal processes (LNP) is greatly reduced with no apparent involvement of the MAX, resulting in a very small epithelial seam
• cleft lip may be caused by inadequate contact between the MNP and MAX, due to morphological differences, exacerbated by reduced apoptosis and seam persistence
• occasionally at E13.5
• frequently at E13.5




Genotype
MGI:5308087
cn9
Allelic
Composition
Cd207tm2.1(cre)Bjec/Cd207+
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Genetic
Background
involves: 129S4/SvJaeSor * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd207tm2.1(cre)Bjec mutation (0 available); any Cd207 mutation (25 available)
Tgfbr1tm1.1Karl mutation (1 available); any Tgfbr1 mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• mice lack almost all CD207-positive dendritic cells (DCs) in the epidermis
• contact hypersensitivity assessed by ear swelling is attenuated at 24 hours after hapten challenge relative to wild-type controls

hematopoietic system
• mice lack almost all CD207-positive dendritic cells (DCs) in the epidermis




Genotype
MGI:5523277
cn10
Allelic
Composition
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+
Genetic
Background
involves: 129S/Sv * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
A1cfTg(Myh6-cre/Esr1*)1Jmk mutation (5 available); any A1cf mutation (39 available)
Tgfbr1tm1.1Karl mutation (1 available); any Tgfbr1 mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• by 6 days following IP tamoxifen treatment (80 mg/kg BW for 5 days), 60% mortality of treated mice is observed

cardiovascular system
N
• treatment of mice with oral dose of 160 mg/kg BW per day raloxifene for 21 days resulted in similar recombinase activity as the tamoxifen regimen, but does not cause any cardiac dysfunction; lower (20 mg/kg BW) oral tamoxifen treatment for 21 days does not cause dysfunction
• mice die by 6 days post-treatment (80 mg/kg BW IP for 5 days) from severe dilated cardiomyopathy
• oral delivery of 80 mg/kg BW tamoxifen for 7 days does not result in any mortality but treated mice exhibit a significant but reversible dilated cardiomyopathy
• 3 days after oral tamoxifen treatment, cardiac depression peaks with fractional shortening decreasing from 61 to 27% and end-diastolic dimension increasing significantly

muscle
• mice die by 6 days post-treatment (80 mg/kg BW IP for 5 days) from severe dilated cardiomyopathy
• oral delivery of 80 mg/kg BW tamoxifen for 7 days does not result in any mortality but treated mice exhibit a significant but reversible dilated cardiomyopathy
• 3 days after oral tamoxifen treatment, cardiac depression peaks with fractional shortening decreasing from 61 to 27% and end-diastolic dimension increasing significantly





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
05/28/2024
MGI 6.13
The Jackson Laboratory